Surgery Doctors in Portage, MI Accepting Medicare

3 Surgery doctors found. Showing 1 - 3

Dr. Karen M Buckley, MD Surgery - Plastic and Reconstructive Surgery Medicare: Accepting Medicare Assignments Practice Location: 7901 S 12th St Ste 100, Portage, MI 49024 Phone: 269-372-3000

Kenneth M Vandervelde Jr., MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 7775 Angling Rd, Portage, MI 49024 Phone: 269-321-9970    Fax: 269-321-9972

Dr. Kimberly Clawson, Surgery - Plastic and Reconstructive Surgery Medicare: Accepting Medicare Assignments Practice Location: 7901 S 12th St, Portage, MI 49024 Phone: 269-372-3000

News Archive

Patient's health interests are the most important factor to consider in ethical decision making

The majority of pharmacists across the profession who were involved in a UK study reported the patient's health interests as the most important factor to consider in ethical decision making. They also indicated that regulation seems to play a very important part in moral decision making.

Disrupted memory pathways uncovered in epilepsy patients

A study in rats, backed up by results in patients, has revealed how interictal epileptiform discharges may lead to memory impairments in patients with epilepsy.

A review of natural immunity, vaccines, and variants in SARS-CoV-2 reinfection

In a literature review article published in the Journal of Community Hospital Internal Medicine Perspectives, authors from the US performed a thorough investigation of previous studies and case reports of SARS-CoV-2 reinfection. This review discusses the role of natural immunity, vaccines, and SARS-CoV-2 variants in reinfection.

Ironwood Pharmaceuticals' IPO: Underwriters exercise over-allotment option

Ironwood Pharmaceuticals, Inc. today announced that the underwriters of its February 2, 2010 initial public offering (IPO) have exercised their over-allotment option in full on an additional 2.5 million shares of Ironwood's Class A common stock. With the completion of the IPO and the exercise of the over-allotment option, Ironwood has approximately 97.4 million shares of common stock outstanding (approximately 19.2 million shares of Class A common stock and 78.2 million shares of Class B common stock).

Avila's AVL-292 demonstrates disease-modifying effects in prophylactic, therapeutic models of rheumatoid arthritis

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, today announced results of preclinical studies demonstrating that its clinical candidate, AVL-292, potently inhibits B cell receptor signaling, and demonstrates efficacy in a rodent model of rheumatoid arthritis. These new data were presented Saturday, June 26, 2010 at the Federation of Clinical Immunology Societies (FOCIS) 2010 annual meeting in Boston, MA.

Read more Medical News

› Verified 5 days ago